It's not capital expenditure on Deloraine that is the problem, it's the Operating expenses.
For every $10M of Sales bubs makes, it losses $1M cash, excluding operating expenses. It cost BUBS $11,755,000 cash to manufacture $10,676,000 sales.
If you cut advertising and marketing - sales goes down.
If you cut staff costs - No SAMR, No USFDA.
If you cut admin and corporate costs - No SAMR, No USFDA, No Court cases.
this is not worth $75M Market Cap
It's not capital expenditure on Deloraine that is the problem,...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $138.4M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.0¢ | 15.3¢ | $262.4K | 1.690M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 243370 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 1279258 | 15 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| BUB (ASX) Chart |